RxSight, Inc.
RxSight, Inc. (RXST) Financial Performance & Income Statement Overview
Review RxSight, Inc. (RXST) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
RxSight, Inc. (RXST) Income Statement & Financial Overview
Review RxSight, Inc. RXST income statement with detailed quarterly and annual figures.
Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
---|---|---|---|---|
Revenue | $37.90M | $40.21M | $45.41M | $34.89M |
Cost of Revenue | $9.57M | $11.43M | $20.19M | $10.64M |
Gross Profit | $28.33M | $28.79M | $25.22M | $24.25M |
Gross Profit Ratio | $0.75 | $0.72 | $0.56 | $0.70 |
R&D Expenses | $10.37M | $9.21M | $8.84M | $8.29M |
SG&A Expenses | $28.64M | $28.21M | $25.61M | $24.29M |
Operating Expenses | $39.003M | $37.42M | $34.45M | $32.58M |
Total Costs & Expenses | $48.57M | $48.84M | $54.63M | $43.22M |
Interest Income | $0.00 | $2.71M | $2.91M | $2.28M |
Interest Expense | -$6000.00 | $5000.00 | $5000.00 | $6000.00 |
Depreciation & Amortization | $0.00 | $523000.00 | $1.14M | $820000.00 |
EBITDA | -$10.67M | -$5.40M | -$5.18M | -$5.24M |
EBITDA Ratio | -$0.28 | -$0.13 | -$0.11 | -$0.15 |
Operating Income | -$10.67M | -$8.63M | -$9.23M | -$8.33M |
Operating Income Ratio | -$0.28 | -$0.21 | -$0.20 | -$0.24 |
Other Income/Expenses (Net) | $2.50M | $2.70M | $2.90M | $2.27M |
Income Before Tax | -$8.17M | -$5.93M | -$6.33M | -$6.06M |
Income Before Tax Ratio | -$0.22 | -$0.15 | -$0.14 | -$0.17 |
Income Tax Expense | $18000.00 | $12000.00 | $13000.00 | $16000.00 |
Net Income | -$8.19M | -$5.94M | -$6.34M | -$6.08M |
Net Income Ratio | -$0.22 | -$0.15 | -$0.14 | -$0.17 |
EPS | -$0.20 | -$0.15 | -$0.16 | -$0.16 |
Diluted EPS | -$0.20 | -$0.15 | -$0.16 | -$0.16 |
Weighted Avg Shares Outstanding | $40.51M | $40.36M | $39.79M | $38.46M |
Weighted Avg Shares Outstanding (Diluted) | $40.51M | $40.36M | $39.79M | $38.46M |
Over the past four quarters, RxSight, Inc. demonstrated steady revenue growth, increasing from $34.89M in Q2 2024 to $37.90M in Q1 2025. Operating income reached -$10.67M in Q1 2025, maintaining a consistent -28% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$10.67M, reflecting operational efficiency. Net income dropped to -$8.19M, with EPS at -$0.20. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan